company background image
EMBT logo

Ember Therapeutics OTCPK:EMBT Stock Report

Last Price

US$0.0001

Market Cap

US$4.3k

7D

0%

1Y

n/a

Updated

18 Dec, 2023

Data

Company Financials

Ember Therapeutics, Inc.

OTCPK:EMBT Stock Report

Market Cap: US$4.3k

EMBT Stock Overview

Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company.

EMBT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Ember Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ember Therapeutics
Historical stock prices
Current Share PriceUS$0.0001
52 Week HighUS$0.0002
52 Week LowUS$0.0001
Beta0
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-99.99%
5 Year Change-99.90%
Change since IPO-99.97%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

EMBTUS PharmaceuticalsUS Market
7D0%-0.06%2.1%
1Yn/a23.6%30.4%

Return vs Industry: Insufficient data to determine how EMBT performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how EMBT performed against the US Market.

Price Volatility

Is EMBT's price volatile compared to industry and market?
EMBT volatility
EMBT Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement6.0%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.0%

Stable Share Price: EMBT has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine EMBT's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010n/aJoe Hernandezhttps://www.embertx.com

Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport’s syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease.

Ember Therapeutics, Inc. Fundamentals Summary

How do Ember Therapeutics's earnings and revenue compare to its market cap?
EMBT fundamental statistics
Market capUS$4.31k
Earnings (TTM)US$0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EMBT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$0
EarningsUS$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did EMBT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.